Pharmacology, Biochemistry and Behavior 100 (2012) 425–430
Contents lists available at SciVerse ScienceDirect
Pharmacology, Biochemistry and Behavior
journal homepage: www.elsevier.com/locate/pharmbiochembeh
Lithium attenuates pain-related behavior in a rat model of neuropathic pain: Possible
involvement of opioid system
Hamid R. Banafshe, Azam Mesdaghinia, Meysam Noorani Arani, Mehdi Honarkar Ramezani,
Azhdar Heydari, Gholam A. Hamidi ⁎
Physiology Research Center, Department of Physiology & Pharmacology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
a r t i c l e
i n f o
Article history:
Received 31 July 2010
Received in revised form 12 September 2011
Accepted 2 October 2011
Available online 8 October 2011
Keywords:
Neuropathic pain
Lithium
Opioid
Rat
a b s t r a c t
Lithium is a major drug for bipolar disorder and mania. Recently, many studies have shown the neuroprotective effect of lithium in different models of neurodegenerative diseases. The present study was carried out to
examine the effect of lithium in a rat model of neuropathic pain induced by partial sciatic nerve ligation and
the possible role of opioid system in this effect. To do so, animals received acute injection of saline, lithium
(5, 10 and 15 mg/kg,) and naloxone (1 mg/kg) or the combination of naloxone (1 mg/kg) with lithium
(10 mg/kg) intraperitoneally on the testing days. Thermal hyperalgesia, mechanical and cold allodynia
were measured on the days 3, 5, 7, 10 and 14 after surgery. Lithium decreased thermal hyperalgesia scores
with dose of 5, 10 and 15 mg/kg and cold and mechanical allodynia scores with dose of 10 and 15 mg/kg, significantly. The opioid antagonist naloxone prevented the effect of lithium on thermal hyperalgesia and mechanical allodynia while it did not show any effect on the acetone-induced cold allodynia. Our results
suggest that lithium can be considered as a therapeutic potential for the treatment of some aspects of neuropathic pain and that the opioid system may be involved in the lithium-induced attenuation of thermal hyperalgesia and mechanical allodynia.
© 2011 Elsevier Inc. All rights reserved.
1. Introduction
Neuropathic pain as a consequence of nerve injury or dysfunction
is one of the most difficult challenges in pain treatment. The pathophysiology of neuropathic pain is complex, involving both peripheral
and central mechanisms, such as sensitization of afferent nociceptor
terminal, alteration of neurotransmitters release and ion channel expression, ectopic activity of neurons, anatomical reorganization and
changes in inhibitory pain pathways (Zhuo, 2007; Coderre et al.,
1993; Latremoliere and Woolf, 2009). There are several categories
of medications that can be used in management of neuropathic pain
including anticonvulsant, tricylic antidepressant, local anesthetics
and opioids. However, they are limited by incomplete efficacy and
dose-limiting adverse effects (Jensen et al., 2009; Hansson and
Dickenson, 2005).
Lithium is widely used in treatment of bipolar disorder (Brunello
and Tascedda, 2003). Recently, increasing body of evidences report
the neuroprotective effects of lithium against cell injuries caused by
different noxious stimuli in cultured cells and animal model of neurodegenerative diseases (Chuang et al., 2002; Wada et al., 2005). These
stimuli include glutamate excitotoxicity, β amyloid peptide, focal
ischemia, potassium deprivation, growth factor withdrawal, irradiation and taupathies caused by tau proteins (Nonaka et al., 1998; Sun
et al., 2002; Pérez et al., 2003). Many studies have also shown the interaction between the lithium and the opioid system. For example,
lithium can reduce morphine tolerance and dependence (Dehpour
et al., 1995; Alborzi et al., 2006), change morphine-induced analgesia
(Johnston and Westbrook, 2004; Dehpour et al., 1994) and inhibit
modulatory effects of morphine on pentylenetetrazole-induced seizure (Honar et al., 2004). Chronic lithium administration is also demonstrated to increases mu-opioid receptor expression in rats'
forebrain (de Gandarias et al., 2000). Lithium also stimulates the release of beta-endorphin, met-enkephalin and dynorphin in brain via
an inhibition of autoreceptors (Staunton et al., 1982; Burns et al.,
1990; Gillin et al., 1978) and increases dynorphin and prodynorphin
mRNA in the basal ganglia of rats (Sivam et al., 1988). The present
study was conducted to determine the effect of lithium on a rat
model of neuropathic pain and to examine the possible involvement
of the opioid system in this effect.
2. Materials and methods
2.1. Animals and housing conditions
⁎ Corresponding author. Tel.: + 98 361 5550021; fax: + 98 361 5575057.
E-mail address: hamiidi@yahoo.com (G.A. Hamidi).
0091-3057/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.pbb.2011.10.004
The experiments were performed on male Sprague–Dawley rats
(200–250 g) purchased from Razi Institute (Karaj, Iran). They were
426
H.R. Banafshe et al. / Pharmacology, Biochemistry and Behavior 100 (2012) 425–430
housed four per cage, in a room under controlled temperature (23 ±
2 °C), humidity (50%) and lighting (12/12 h light/dark cycle), with
food and water available ad libitum. All experiments were approved
by the ethical committee of Kashan University of Medical sciences
and followed the European Commission Directive (86/609/EEC) for
animal experiments.
2.2. Neuropathic pain model: partial sciatic nerve ligation
The rats were anesthetized with sodium pentobarbital (65 mg/kg)
intraperitoneally (i.p.) and the sciatic nerve ligation was performed
according to the original description of Seltzer (Seltzer et al., 1990).
Briefly, an incision was made at the skin overlying the lateral femur
then the sciatic nerve was exposed and dissected from surrounding
connective tissue near the trocanter, just distal to the branching
point of the posterior biceps semitendinosus nerve. A tight ligature
was tied around 1/3 to 1/2 of the nerve diameter with 8-0 silk suture.
Sham operated rats had the same surgery without any ligature on the
sciatic nerve.
central region of the plantar surface of the hind paw. The stimulation
was applied three times consecutively, pushing down on the hind
paw until the rat withdrew its paw or the fiber bowed. Lifting of the
paw due to normal locomotor behavior was ignored. The smallest filament size which evoked at least two withdrawal responses during
three consecutive applications was considered as withdrawal threshold. Each filament was applied for approximately 1 s and the interstimulus intervals were about 5 s (Chaplan et al., 1994).
2.4. Treatment
In the nerve ligated animals (n = 8 per group), different doses of
lithium chloride (5, 10 and 15 mg/kg; i.p.), were administered only
on the days 3, 5, 7, 10 and 14 after the surgery without any injection
on the other days. In the control group (n = 8), rats received equal
volume of normal saline instead of lithium chloride. To evaluate the
involvement of opioid system on lithium-induced effects, the opioid
antagonist naloxone (1 mg/kg, i.p.) was acutely administered
15 min prior to optimum dose of lithium on the days 3, 5, 7, 10 and
14 after the surgery.
2.3. Behavioral tests of neuropathic pain
2.5. Statistical analysis
Hyperalgesia to noxious thermal stimulus and allodynia to cold
and mechanical stimuli were determined as behavioral score of neuropathic pain by using the radiant heat plantar, acetone and von Frey
test, respectively. These tests were performed during the day portion
of the circadian cycle (09:00–16:00 h). After cage exploration and
major grooming activities ceased, we made the behavioral tests. The
behavioral scores of neuropathic pain were determined 1 day before
the surgery as the baseline value and also 30 min after the injections
on days 3, 5, 7, 10 and 14 after the surgery.
2.3.1. Thermal hyperalgesia (plantar test)
Thermal hyperalgesia was assessed as previously reported
(Hargreaves et al., 1988). Paw withdrawal latency in response to radiant heat was measured by using plantar test apparatus (Ugo Basile,
Varese, Italy). Rats were placed within a Plexiglass enclosure (but
not restrained) on a transparent glass floor. An infrared beam that
constitutes the heat source was moved beneath the mid-plantar
surface of the hind paw. Thermal withdrawal latency was defined as
the latency (seconds) between the heat stimulus onset and paw withdrawal using a feedback-controlled shut-down unit. A cut-off time of
22 s was used to avoid tissue damage. Each paw was tested three
times alternatively at minimum intervals of 5 min between stimulation to avoid sensitization of the hind paw. The mean latency of the
withdrawal responses for ipsilateral (operated) and contralateral
(non-operated) paws was calculated separately.
2.3.2. Cold allodynia (acetone test)
Cold allodynia was measured using the acetone spray test
(evaporation-evoked cooling) described by Choi (Choi et al., 1994).
Rats were placed on a wire mesh floor; acetone bubbles formed at
the end of a tube connected to a syringe were applied 5 times (at
5 min intervals) to the plantar surface of the hind paw. The frequency
of paw withdrawal was expressed as a percentage (the number of
paw withdrawals/number of trials × 100).
2.3.3. Mechanical allodynia (von Frey filament stimulation)
Mechanical allodynia was quantified by measuring the hind paw
withdrawal response to von Frey filament. We studied the effect of
von Frey filament stimulation (with bending forces ranging from 2
to 60 g, Stolting Inc., Wood Dale, IL). Rats were placed on a mesh
(0.8 × 0.8 cm cell) floor, covered by an inverted transparent plastic
box (18 × 18 × 25 cm) and allowed to adapt for approximately
15 min, or until exploratory behavior ceased. A series of von Frey filament stimuli were delivered in an ascending order of forces to the
All data are presented as Mean ± SEM and differences are considered significant if the P value was less than 0.05. Values for behavioral
response were analyzed using analysis of variance (ANOVA) with repeated measures followed by Tukey's honest squares difference
(HSD) test. Drug treatment was considered as the between-subjects
and day as within-subjects.
3. Results
3.1. The effect of lithium on behavioral tests of neuropathic pain
The majority of the animals appeared healthy and well-groomed.
The rats did not show any sign of autotomy after the sciatic nerve ligation and common adverse effects of lithium such as tremor, ataxia and
convulsion. The gesture of ipsilateral paw was slightly altered; but this
did not interfere with the normal activity of the rats. Lithium had no effect on behavioral responses evoked from the sham-operated animals
and did not show any analgesic effect (data not shown).
3.1.1. Thermal hyperalgesia
Partial sciatic nerve ligation decreased paw withdrawal latency to
the thermal stimulus in ipsilateral (P b 0.001) (Fig. 1a1) and contralateral paw (P b 0.05) significantly (Fig. 1a2), but sham operation did not
produce any significant change in withdrawal latency. Lithium chloride (5, 10 and 15 mg/kg) blocked thermal hyperalgesia in ipsilateral
paw dose-dependently (Fig. 1a1) and also increased withdrawal latency of contralateral paw but this change was only significant with
the dose of 15 mg/kg on 14th day (Fig. 1a2).
3.1.2. Cold allodynia
The results of the behavioral tests for cold allodynia have been
shown in Fig. 1b. The ipsilateral paw of nerve ligated animals became
much more sensitive to acetone application (P b 0.001) but the contralateral paw remained unresponsive throughout the experiments
for all the groups. Sham operation did not produce any modification
of the nociceptive response. Lithium chloride (10 and 15 mg/kg) significantly reduced the withdrawal frequency in comparison with control group (P b 0.001) (Fig. 1b).
3.1.3. Mechanical allodynia
Fig. 1c shows the effects of lithium chloride on mechanical allodynia. Partial sciatic nerve ligation led to a significant decrease of withdrawal threshold of ipsilateral paw in comparison with sham-
H.R. Banafshe et al. / Pharmacology, Biochemistry and Behavior 100 (2012) 425–430
427
Fig. 1. Effect of lithium on development of neuropathic pain in sciatic nerve ligated rats. The behvioral manifestations of neuropathic pain were evaluated by using plantar test
(a); paw withdrawal latency (S) of ipsilateral (a1) and contralateral paw (a2), acetone test (b); the percentage of foot withdrawals to repeated cold stimuli and von Frey model
(c); mechanical withdrawal threshold (g). The behavioral responses were determined 3, 5, 7, 10 and 14 days after sciatic nerve surgery. The results are expressed as Mean ±
SEM. ** P b 0.01, *** P b 0.001 versus control group, ## P b 0.05, ### P b 0.001 versus sham group.
operated group (P b 0.001). The withdrawal thresholds of contralateral paw ranged from 52.2 to 60 g and 48.1 to 60 g in the nerve ligated
and sham-operated animals respectively. These scores were not different significantly (P > 0.05). Lithium chloride with dose of 10 and
15 mg/kg, significantly increased withdrawal threshold of ipsilateral
paw (P b 0.001).
3.2. The effects of naloxone on lithium-induced effects
Naloxone (1 mg/kg, i.p.) on itself had no effect on behavioral tests
of neuropathic pain in nerve ligated and sham-operated rats. Fig. 2a
shows the effects of naloxone on thermal anti-hyperalgesic effect of
lithium (10 mg/kg). Naloxone significantly prevented antihyperalgesic effect of lithium in radiant heat plantar test (P b 0.001)
(Fig. 2a1). As shown in Fig. 2c, naloxone blocked the anti-allodynic effects of lithium in the von Frey filament test but could not change the
effect of lithium in the acetone test significantly (P > 0.05) (Fig. 2b).
4. Discussion
Our study demonstrated that an acute i.p. injection of lithium attenuates thermal hyperalgesia and mechanical and cold allodynia in
a rat sciatic nerve ligation model of neuropathic pain and potent opioid antagonist naloxone prevents these effects of lithium on hyperalgesia and mechanical allodynia but could not change the effect of
lithium on cold allodynia. Our results are in agreement with previous
data reported that intrathecal injection of lithium reduces neuropathic pain responses in chronic constrictive injury (CCI) model in rats
(Shimizu et al., 2000). No considerable adverse effects of lithium
such as tremor, ataxia or convulsion were observed in the lithiumtreated rats. It seems the absence of adverse effects is expectable because of the low dose of lithium in our experiments. Lithium has no
significant effect on responses evoked from sham-operated animals.
This result is consistent with previous studies that suggested that
the effect of lithium is anti-hyperalgesic rather than analgesic
(Zhang et al., 1994; Shimizu et al., 2000). Lithium decreases exploratory activity, rearing, aggression, and locomotor activity in a dose
range of 32 mg/kg to 127 mg/kg in rats (Tenk et al., 2005). The effect
of lithium on spontaneous behavior is limited to certain behaviors
and certain doses. Changes that occur at therapeutic doses are not
caused by general motor impairment. Indeed, it has been shown
that therapeutic doses of lithium, which effectively alter druginduced locomotion, do not change baseline locomotion in tests
with a sufficient time course (O'Donnell and Gould, 2007).
Lithium is a small monovalent cation with similar ionic radius to
magnesium and inhibits some enzymes through competition for this
essential cofactor. Lithium with therapeutic concentration inhibits
inositol monophosphate phosphatase (IMPase), inositol polyphosphate 1-phosphatase (IPPase), phosphoglucomutase (PGM) and glycogen synthase kinase-3 (GSK-3) (Wada, 2009; Quiroz et al., 2004).
The best-defined targets of lithium are IMPase and IPPase involved
in the normal recycling of membrane phosphoinositides. This recycling is necessary to continue phosphoinositol-mediated signaling in
central nervous system where inositol is not freely available.
Lithium's inhibitory effect on IMPase and IPPase led to the inositol
depletion hypothesis. This hypothesis suggests that lithium exerts
its effect by relative decrease of inositol and thus phosphoinositide
4,5-bisphosphate (PIP2) available for signaling cascades that depend
428
H.R. Banafshe et al. / Pharmacology, Biochemistry and Behavior 100 (2012) 425–430
Fig. 2. Effects of i.p. injection of saline (control), lithium (10 mg/kg), naloxone (1 mg/kg) and lithium (10 mg/kg) + naloxone (1 mg/kg) on heat hyperalgesia in ipsilateral (a1) and
contralateral paw (a2), cold allodynia (b) and mechanical allodynia (c).The results are expressed as Mean ± SEM. ** P b 0.01, *** P b 0.001 versus control group, ### P b 0.001 versus
lithium (10 mg/kg).
on phospoinositides like neurtrophin, tyrosine kinase receptors and
some G protein-mediated signaling pathways (Berridge et al., 1989;
Liou et al., 2007). A number of studies using animal models have indicated that the intracellular phosphatidylinositol (PI) second messenger system has a critical role in development of neuropathic pain
(Mao et al., 1992, 1995; Coderre et al., 1993). It has been also reported
that intrathecal injection of myo-inositol canceled the effect of lithium in the reduction of hyperalgesia and cold allodynia in a rat
model of peripheral neuropathy without any effect on mechanical
allodynia (Shimizu et al., 2000).
Lithium also inhibits glycogen synthase kinase-3 (GSK-3). GSK-3
is a normally active kinase that is a part of many intracellular signaling pathways such as neurotrophic signaling, the insulin phosphatidylinositol 3 kinase (PI3K) and the Wnt pathways (Ryves and
Harwood, 2001). Activation of these pathways inhibits GSK-3 and
this inhibitory effect has been linked to neuroprotection and activation of cell survival signaling pathways (Noble et al., 2005; Wada,
2009). Lithium causes up-regulation of a brain-derived neurotrophic
factor (BDNF) and antiapoptotic Bcl2, down-regulation of apoptotic
p53, caspase and Bax, induction of neuronal regeneration and activation of cAMP response element binding protein (CREB) (Hashimoto et
al., 2002; Chuang, 2004). Several studies have shown the significant
increase in apoptosis and pro-apoptotic Bax, apoptotic proteaseactivating factor-1 (apaf-1), caspase-7 and p53 in neuropathic pain
(de Novellis et al., 2004; Gradl et al., 2004; Scholz et al., 2005).
According to these studies lithium may attenuate neuropathic pain
through up-regulation of cell survival molecules and down- regulation of proapoptotic activity.
Multiple lines of studies have demonstrated interaction between
lithium and opioid system (Honar et al., 2004; Dehpour et al., 1995;
Zarrindast et al., 2008). Lithium stimulates release of betaendorphin, met-enkephalin and dynorphin in brain (Staunton et al.,
1982; Burns et al., 1990) and increases the prodynorphin mRNA
abundance and enkephalin content in striatum (Sivam et al., 1988).
Chronic lithium administration also increases mu-opioid receptor expression (de Gandarias et al., 2000). On the other hand, peripheral
nerve injury results in down-regulation of mu-opioid receptor
(MOR) in dorsal horn of spinal cord (Porreca et al., 1998; Goff et al.,
1998). This loss of spinal MOR is associated with behavioral manifestation of neuropathic pain and the reduction of opioid analgesic effect
(Rashid et al., 2004; Back et al., 2006). Thus, the enhancement of opioid system activity can be considered as one of the possible mechanisms of lithium in attenuation of neuropathic pain. Our results also
showed naloxone prevents the effect of lithium in reduction of heat
hyperalgesia and mechanical allodynia scores while it did not change
its effect on cold allodynia. This difference is probably due to different
nociceptors and neuronal pathways involved in different sensory modalities. Non-noxious tactile stimulus is transmitted chiefly through
low-threshold, large diameter, myelinated Aβ fibers, while cold stimulus is transmitted to the spinal cord through high-threshold, thin
unmyelinated primary C-fiber nociceptors (Yeomans and Proudfit,
1996). In particular, that painful reaction to innocuous thermal stimuli seems not to be due to a simple decrease in nociceptor thresholds.
The increasing body of evidences demonstrated the involvement of
distinctive warm and cold receptors in thermal allodynia (Gautron
et al., 1990; Xing et al., 2007). Recent studies on transient receptor
potential melastatin 8 (TRPM8) knockout mice indicate the involvement of cold and menthol-sensitive receptor TRPM8 in cold allodynia
while it does not have any involvement in mediation of heat or mechanical pain (Dhaka et al., 2007; Chung and Caterina, 2007).
H.R. Banafshe et al. / Pharmacology, Biochemistry and Behavior 100 (2012) 425–430
In addition, it is important to note the evidences for the involvement of the sympathetic nervous system in neuropathic painrelated behavior. Surgical lumbar sympathectomy had no effect on
the mechanical allodynia and mechanical hyperalgesia induced by
spared nerve injury model (SNI). However, the sympathectomy significantly attenuated the cold allodynia induced by SNI (Zhao et al.,
2007). Other studies also demonstrate allodynia is under endogenous
noradrenergic rather than opioidergic control in rat models of neuropathic pain (Yaksh et al., 1995; Kontinen et al., 1998; Xu et al., 1999).
In conclusion, our study showed that lithium reduces behavioral
scores of neuropathic pain and the opioid system may be involved
in the attenuation of heat hyperalgesia and mechanical allodynia induced by lithium. Other mechanisms also may be involved in this effect of lithium, particularly in attenuation of cold allodynia. Further
investigations are required to clarify the other possible mechanisms
of lithium in attenuation of neuropathic pain.
Acknowledgments
This paper has been taken out from the MD degree thesis and supported financially by Vice Chancellor of Research, Kashan University
of Medical Sciences, Kashan, Iran. We would like to thank Dr. A.R.
Dehpour, Tehran University of medical sciences for his administrative
assistance and advice.
References
Alborzi A, Mehr SE, Rezania F, Badakhshan S, Mombeini T, Shafaroodi H, et al. The effect
of lithium chloride on morphine-induced tolerance and dependence in isolated
guinea pig ileum. Eur J Pharmacol 2006;545(2–3):123–8.
Back SK, Lee J, Hong SK, Na HS. Loss of spinal mu-opioid receptor is associated with mechanical allodynia in a rat model of peripheral neuropathy. Pain 2006;123:117–26.
Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a
unifying hypothesis. Cell 1989;59(3):411–9.
Brunello N, Tascedda F. Cellular mechanisms and second messengers: relevance to the
psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol 2003;6(2):
181–9.
Burns G, Herz A, Nikolarakis KE. Stimulation of hypothalamic opioid peptide release by
lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex
vivo study. Neuroscience 1990;36(3):691–7.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile
allodynia in the rat paw. J Neurosci Methods 1994;53(1):55–63.
Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold
allodynia in a rat model of neuropathic pain. Pain 1994;59(3):369–76.
Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium:
can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004;16
(1–2):83–90.
Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, et al.
Neuroprotective effects of lithium in cultured cells and animal models of diseases.
Bipolar Disord 2002;4(2):129–36.
Chung MK, Caterina MJ. TRP channel knockout mice lose their cool. Neuron 2007;54
(3):345–7.
Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to
pathological pain: review of clinical and experimental evidence. Pain 1993;52:
259–85.
de Gandarias JM, Acebes I, Echevarría E, Vegas L, Abecia LC, Casis L. Lithium alters mu
opioid receptor expression in the rat brain. Neurosci Lett 2000;279(1):9-12.
de Novellis V, Siniscalco D, Galderisi U, Fuccio C, Nolano M, Santoro L, et al. Blockade of
glutamate mGlu5 receptors in a rat model of neuropathic pain prevents early overexpression of pro-apoptotic genes and morphological changes in dorsal horn
lamina II. Neuropharmacology 2004;46(4):468–79.
Dehpour AR, Farsam H, Azizabadi-Farahani M. The effect of lithium on morphineinduced analgesia in mice. Gen Pharmacol 1994;25(8):1635–41.
Dehpour AR, Farsam H, Azizabadi-Farahani M. Inhibition of the morphine withdrawal
syndrome and the development of physical dependence by lithium in mice. Neuropharmacology 1995;34(1):115–21.
Dhaka A, Murray AN, Mathur J, Earley TJ, Petrus MJ, Patapoutian A. TRPM8 is required
for cold sensation in mice. Neuron 2007;54(3):371–8.
Gautron M, Jazat F, Ratinahirana H, Hauw JJ, Guilbaud G. Alterations in myelinated fibres in the sciatic nerve of rats after constriction: possible relationships between
the presence of abnormal small myelinated fibres and pain-related behaviour.
Neurosci Lett 1990;111:28–33.
Gillin JC, Hong JS, Yang HY, Costa E. [Met5] Enkephalin content in brain regions of rats
treated with lithium. Proc Natl Acad Sci U S A 1978;75(6):2991–3.
Goff JR, Burkey AR, Goff DJ, Jasmin L. Reorganization of the spinal dorsal horn in models
of chronic pain: correlation with behaviour. Neuroscience 1998;82(2):559–74.
429
Gradl G, Gaida S, Gierer P, Mittlmeier T, Vollmar B. In vivo evidence for apoptosis, but
not inflammation in the hindlimb muscle of neuropathic rats. Pain 2004;112(1–2):
121–30.
Hansson PT, Dickenson AH. Pharmacological treatment of peripheral neuropathic pain
conditions based on shared commonalities despite multiple etiologies. Pain
2005;113:251–4.
Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32(1):77–88.
Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang D-M. Lithium induces brainderived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential
step for neuroprotection against glutamate excitotoxicity. Neuropharmacology
2002;43:1173–9.
Honar H, Riazi K, Homayoun H, Demehri S, Dehghani M, Vafaie K, et al. Lithium inhibits
the modulatory effects of morphine on susceptibility to pentylenetetrazoleinduced clonic seizure in mice: involvement of a nitric oxide pathway. Brain Res
2004;1029(1):48–55.
Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains.
Curr Opin Neurol 2009;22(5):467–74.
Johnston IN, Westbrook RF. Inhibition of morphine analgesia by lithium: role of peripheral and central opioid receptors. Behav Brain Res 2004;151(1–2):151–8.
Kontinen VK, Paananen S, Kalso EA. Effects of systemic morphine in the spinal nerveligation model of neuropathic pain in rats. Eur J Pain 1998;2:35–42.
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity
bycentral neural plasticity. J Pain 2009;10(9):895–926.
Liou JT, Liu FC, Hsin ST, Yang CY, Lui PW. Inhibition of the cyclic adenosine monophosphate pathway attenuates neuropathic pain and reduces phosphorylation of cyclic adenosine monophosphate response element-binding in the spinal cord after
partial sciatic nerve ligation in rats. Anesth Analg 2007;105(6):1830–7.
Mao J, Price DD, Mayer DJ, Hayes RL. Pain-related increases in spinal cord membrane
bound protein kinase C following peripheral nerve injury. Brain Res 1992;588:
144–9.
Mao J, Price DD, Phillips LL, Lu J, Mayer DJ. Increase in protein kinase C gamma immunoreactivity in the spinal cord dorsal horn of rats with painful mononeuropathy.
Neurosci Lett 1995;198(2):75–8.
Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen
synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration
in vivo. Proc Natl Acad Sci U S A 2005;102:6990–5.
Nonaka S, Hough CJ, Chuang D-M. Chronic lithium treatment robustly protects neurons
in the central nervous system against excitotoxicity by inhibiting N-me thyl-Daspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998;95:
2642–7.
O'Donnell KC, Gould TD. The behavioral actions of lithium in rodent models: leads to
develop novel therapeutics. Neurosci Biobehav Rev 2007;31(6):932–62.
Pérez M, Hernández F, Lim F, Díaz-Nido J, Avila J. Chronic lithium treatment decreases
mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis
2003;5:301–8.
Porreca F, Tang QB, Bian D, Riedl M, Elde R, Lai J. Spinal opioid mu receptor expression
in lumbar spinal cord of rats following nerve injury. Brain Res 1998;795:197–203.
Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 2004;4(5):
259–72.
Rashid MH, Inoue M, Toda K, Ueda H. Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J
Pharmacol Exp Ther 2004;309:380–7.
Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for
magnesium. Biochem Biophys Res Commun 2001;280(3):720–5.
Scholz J, Broom DC, Youn DH, Mills CD, Kohno T, Suter MR, et al. Blocking caspase
activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in
lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 2005;25
(32):7317–23.
Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders
produced in rats by partial sciatic nerve injury. Pain 1990;43(2):205–18.
Shimizu T, Shibata M, Wakisaka S, Inoue T, Mashimo T, Yoshiya I. Intrathecal lithium
reduces neuropathic pain responses in a rat model of peripheral neuropathy.
Pain 2000;85:59–64.
Sivam SP, Takeuchi K, Li S, Douglass J, Civelli O, Calvetta L, et al. Lithium increases
dynorphin A(1–8) and prodynorphin mRNA levels in the basal ganglia of rats.
Brain Res 1988;427(2):155–63.
Staunton DA, Deyo SN, Shoemaker WJ, Ettenberg A, Bloom FE. Effects of chronic lithium
on enkephalin systems and pain responsiveness. Life Sci 1982;31:1837–40.
Sun X, Sato S, Murayama O, Murayama M, Park J-M, Yamaguchi H, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein
C100. Neurosci Lett 2002;321:61–4.
Tenk CM, Kavaliers M, Ossenkopp KP. Dose response effects of lithium chloride on conditioned place aversions and locomotor activity in rats. Eur J Pharmacol 2005;515:
117–27.
Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen
synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci
2009;110(1):14–28.
Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against
acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci
2005;99(4):307–21.
Xing H, Chen M, Ling J, Tan W, Gu JG. TRPM8 mechanism of cold allodynia after chronic
nerve injury. J Neurosci 2007;27(50):13680–90.
Xu M, Kontinen VK, Kalso E. Endogenous noradrenergic tone controls symptoms of
allodynia in the spinal nerve ligation model of neuropathic pain. Eur J Pharmacol
1999;366:41–5.
430
H.R. Banafshe et al. / Pharmacology, Biochemistry and Behavior 100 (2012) 425–430
Yaksh TL, Pogrel JW, Lee YW, Chaplan SR. Reversal of nerve ligation-induced allodynia
by spinal alpha 2-adrenoceptor agonists. J Pharmacol Exp Ther 1995;272:207–14.
Yeomans DC, Proudfit HK. Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: behavioral evidence. Pain 1996;68:133–40.
Zarrindast MR, Lahmi A, Ahamadi S. Possible involvement of mu-opioid receptors in effect of lithium on inhibitory avoidance response in mice. J Psychopharmacol
2008;22(8):865–71.
Zhang LJ, Han NL, Han JS. Regulation by lithium of the antagonistic effect of cholecystokinin octapeptide on ohmefentanyl-induced antinociception. Neuropharmacology 1994;33. 123–126.
Zhao C, Chen L, Tao YX, Tall JM, Borzan J, Ringkamp M, et al. Lumbar sympathectomy
attenuates cold allodynia but not mechanical allodynia and hyperalgesia in rats
with spared nerve injury. J Pain 2007;8(12):931–7.
Zhuo M. Neuronal mechanism for neuropathic pain. Mol Pain 2007;3:1–9.